Published in Medicine and Law Weekly, October 15th, 2004
According to a study from France, "Preclinical immunogenicity studies of 12 malaria peptides, selected from four Plasmodium falciparum antigens, namely, LSA1, LSA3, SALSA, and STARP, that are expressed at the pre-erythrocytic (sporozoite and liver) stages of the human parasite were carried out in chimpanzees. To strengthen their immunogenicity, six of these synthetic peptides were modified by the C-terminal addition of a single palmitoyl chain (lipopeptides) and delivered without adjuvant, whereas the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly